clinical trial · NCT01357668
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
Bristol-Myers Squibb·—·active not recruiting·n = 800
Juvenile Idiopathic Arthritis
brief summary
The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.
started
Jan 30, 2013
primary completion
Jan 2, 2029
completion
Jan 2, 2029
last updated
Sep 25, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol